Lutz B. Giebel

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

Logical Therapeutics, Inc. develops products that treat diseases associated with inflammation. It provides a platform of bio-activated prodrugs for the chronic treatment of arthritis. Its bio-activated NSAID prodrugs are chemical entities that are designed to reduce the incidence of GI ulcers and improve GI tolerability in patients who require chronic NSAID treatment. The company was founded by Carolyn E. Green in 2005 and is headquartered in Waltham, MA.

ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases.

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA.

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

Spybiotech Ltd. develops molecular superglue which it believes can be used to create vaccines. The company was founded by Sumit Biswas and is headquartered in Oxford, the United Kingdom.

IpiNovyx Bio, Inc. is a drug development and platform technology company that focuses on developing novel therapeutics to treat autoimmune and inflammatory diseases through selective inhibition of the immunoproteasome. The company is based in West Nyack, NY. The company's platform technology enables highly selective, reversible, and non-toxic inhibition of various immune cell types, with applications across a range of indications with underlying immunopathology. Orange Grove Bio (OGB) is an emerging, preclinical, capital allocation, and asset development biotech company that partners with universities and entrepreneurs to develop innovative treatments for important diseases, particularly cancer and immune disorders. The company was founded by Jim Graham, and the CEO is Marc Appel.

Orange Grove Bio LLC is a preclinical biotech company that partners with universities and entrepreneurs to develop innovative treatments for important diseases, particularly cancer and immune disorders. The company is based in Cincinnati, OH. The company fosters strong relationships with entrepreneurs and technology transfer offices outside of the traditional medical technology hubs. Orange Grove Bio's team possesses more than one hundred years of drug development and company creation experience, allowing it to build and finance innovative programs from the research and development stage to clinical trials. The company was founded by Marc Appel. Marc Appel has been the CEO since incorporation.

Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA.